


GSK COVID-19 Solutions

November 2020

GSK Strategy for COVID-19 response includes both preventative and therapeutic approaches



VIR-7831 and otilimab are in development and have NOT been approved anywhere in the world.
anti-GM-CSF = anti-granulocyte macrophage colony stimulating factor; mAbs = monoclonal antibody

GSK and Sanofi in unprecedented collaboration to develop adjuvanted COVID-19 vaccine



- Two of the world's biggest vaccine companies
- Proven technologies
- Ability to manufacture at scale – 1 bn dose commitment from 2021
- Long history of commitment to access

Adjuvanted COVID-19 vaccine:

- Phase I/II clinical trial started in September 2020
- Phase III expected to start end-2020, pending Ph I/II results
- If successful and subject to regulatory considerations, companies aim to make adjuvanted vaccine available by H2 2021

GSK – VIR Biotechnology Collaboration



To identify and accelerate new anti-viral antibodies



- Collaborating with Vir Biotechnology to identify and accelerate new anti-viral antibodies which could be used as therapeutic or preventative options to fight this and future outbreaks
- Using Vir's monoclonal antibody platform and GSK's expertise in functional genomics

VIR-7831 is in development and has NOT been approved anywhere in the world.
GSK does not have the rights to Vir-7831 in China, Hong Kong or Taiwan.

VIR 7831 (GSK4182136): Monoclonal Antibody

- Phase 3 of the COMET-ICE efficacy trial ongoing
- Results for the primary endpoint are expected in the first quarter of 2021
- If the study shows positive data, GSK will work with regulators to make the medicine available to patients as quickly as possible

GSK Otilimab



- Otilimab is a monoclonal antibody, potential treatment for patients who have been hospitalised with severe pulmonary complications related to COVID-19
- It is also being tested in late-stage clinical trials as a potential new treatment for rheumatoid arthritis
- It works by blocking the effects of GM-CSF (granulocyte-macrophage colony-stimulating factor) which is a cytokine found in high levels in patients with COVID-19

Otilimab: Anti-GM-CSF Monoclonal Antibody

- **5.1.2e** (Otilimab in Severe COVID-19 Related Disease) efficacy trial ongoing in UK
- Primary endpoint headline results expected H1 2021
- If the study shows positive data, GSK will work with regulators to make the medicine available to patients as quickly as possible

Otilimab is in development and has NOT been approved anywhere in the world.